StemBond is enabling the next generation of cell-based medicine
We believe in a world where no one hears ‘there are no treatment options left’
Improving cell culture is the fastest way to make advanced therapies safer, cheaper, and more available – driving better patient outcomes.
Cells in the lab don’t behave like cells in the body
However, medicines and therapies rely on experiments with human cells, often cultured in plastic environments.
Advanced therapies need next-generation culture environments. This is where our SENCE™ platform comes in.
Lab cell culture experiments suffer on several key fronts:
Environments lack physiological accuracy, limiting predictive power
Cells behave differently in vitro than they do in the human body
Research relies heavily on animal cells, reducing translational relevance
The SENCE™ Platform
Our environments faithfully replicate the niches cells occupy in the body, and they scale seamlessly with your needs, from well plates to flasks to bioreactors. This consistency provides a stable environment from early discovery through to clinical delivery.
Biomimetic coating
Producing pure cell populations, exactly to researchers needs, without any unwanted 'extras'.
Sustained function
Cells keep working properly for much longer on standard plates, extending research windows significantly.
Highly scalable
A technology that works and scales across workflows, from plates, flasks and beads, to bioreactors.
SENCE™ enables multiple product families
A few examples include:
The core technology platform material is precisely tuned, together with media conditions, to create complete cell culture environments that replicate diverse human tissues.
Lymph node environment
We are developing a base environment that captures the structural and mechanical features of the lymph node. This will provide the foundation for exploring immune cell behaviour and for future tuning into specific applications, such as T cell culture.
Liver environment
A developing niche designed to reflect the mechanobiology of liver tissue. Our aim is to create a platform that supports studies of liver cell development and function, forming the groundwork for future tuning towards hepatocyte, cholangiocyte, and metabolic applications.
Brain environment
An environment that reflects the physical and structural cues of brain tissue. This foundation is intended to support investigations of neural and glial biology, with the potential to be tuned for applications in ageing, repair, and disease modelling.
Joint environment
A pilot environment to model the unique stiffness and extracellular structure of cartilage. It is designed to provide a baseline setting for maintaining chondrocyte identity and mesenchymal cell behaviour, forming the starting point for future tuning toward joint regeneration and arthritis research.
Your environment
With SENCE™, you can work with us to design and build an environment tailored to your research. Together, we’ll tune the mechanics and biochemistry to create the right conditions for your specific cells, enabling a true-to-life model of your choice.
The opportunity to create a comprehensive array of products
Driven by customer needs, it will be possible within each distinct environment to create specific applications. These will be ready-to-use products and will not require further tuning by customers in their own labs.
Better patient outcomes start with better cell culture
Our platform creates a scalable foundation for future products and therapies. By recreating complete cell environments in the lab, we enable safer, more effective medicines for patients everywhere.
For investors
Be part of a $170B market opportunity. We’ve raised pre-seed and are now raising seed
Request our pitch deckWe’re passionate about enabling a world where new medicines are affordable and effective, and no patient hears “there are no treatment options left.”
StemBond Technologies is an enabling platform company, set to revolutionise cell-based medicine.
Meet the team
Built for real-world impact
Adopted by 10+ leading Cambridge research groups
Backed by leading investors
